NCT03083353View on ClinicalTrials.gov

Isradipine Enhancement of Virtual Reality Cue Exposure for Smoking Cessation

EARLY_PHASE1CompletedINTERVENTIONAL
Enrollment

78

Participants

Timeline

Start Date

January 22, 2020

Primary Completion Date

June 14, 2023

Study Completion Date

June 14, 2023

Conditions
Nicotine DependenceSmoking, CigaretteSmoking CessationSmoking BehaviorsSmoking ReductionCraving
Interventions
DRUG

Isradipine

Isradipine will be administered 90 minutes prior to the initiation of cue exposure.

BEHAVIORAL

Cue Exposure

Participants will be exposed to visual smoking cues (i.e., immersive 360 degree video environments) delivered through consumer virtual reality headset and handle cigarette packs to activate and extinguish craving.

Trial Locations (1)

78712

University of Texas at Austin, Austin

All Listed Sponsors
collaborator

National Institute on Drug Abuse (NIDA)

NIH

lead

University of Texas at Austin

OTHER

NCT03083353 - Isradipine Enhancement of Virtual Reality Cue Exposure for Smoking Cessation | Biotech Hunter | Biotech Hunter